Literature DB >> 7729308

Hyperglycemia and microvascular and macrovascular disease in diabetes.

R Klein1.   

Abstract

In summary, over the past 16 years, since the publication of Kelly West's book, epidemiological study has provided better insight into the relation of hyperglycemia and diabetic complications. Data from the WESDR demonstrate a strong consistent relationship between hyperglycemia and the incidence and progression of microvascular (diabetic retinopathy, loss of vision, and nephropathy) and macrovascular (amputation and cardiovascular disease mortality) complications in people with IDDM and NIDDM (Figs. 19 and 20). The DCCT has demonstrated that intensive insulin therapy will reduce the incidence and progression of microvascular complications in people with IDDM (22). A number of further challenges await laboratory scientists and epidemiologists regarding hyperglycemia in people with diabetes. There is a need to understand the relation of hyperglycemia to pathogenetic mechanisms that lead to the development of specific complications, to develop new methods to detect and physiologically treat hyperglycemia, and to develop better methods of primary and secondary prevention of diabetic complications in people with IDDM and NIDDM.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7729308     DOI: 10.2337/diacare.18.2.258

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  145 in total

Review 1.  [The COMBO project. Criteria and guidelines for combined therapy of type 2 diabetes. Consensus document (and II)].

Authors:  A Goday Arno; A Goday Arno; F Alvarez Guisasola; J Díez Espino; I Fernández Fernández; D Tórtola Graner; D Acosta Delgado; M Aguilar Diosdado; J Herrera Pombo; L Felipe Pallardo
Journal:  Aten Primaria       Date:  2001-03-31       Impact factor: 1.137

2.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors:  I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

3.  Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.

Authors:  Faramarz Ismail-Beigi; Timothy E Craven; Patrick J O'Connor; Diane Karl; Jorge Calles-Escandon; Irene Hramiak; Saul Genuth; William C Cushman; Hertzel C Gerstein; Jeffrey L Probstfield; Lois Katz; Ulrich Schubart
Journal:  Kidney Int       Date:  2011-12-14       Impact factor: 10.612

4.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.

Authors:  A I Adler; I M Stratton; H A Neil; J S Yudkin; D R Matthews; C A Cull; A D Wright; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

5.  Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin.

Authors:  T Nakagami
Journal:  Diabetologia       Date:  2004-02-18       Impact factor: 10.122

Review 6.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

7.  Hypoglycemic effects of intraluminal intestinal electrical stimulation in healthy volunteers.

Authors:  Jinsong Liu; Yifei Xiang; Xian Qiao; Yu Dai; Jiande D Z Chen
Journal:  Obes Surg       Date:  2011-02       Impact factor: 4.129

8.  Standards of medical care in diabetes--2011.

Authors: 
Journal:  Diabetes Care       Date:  2011-01       Impact factor: 19.112

Review 9.  Cardiovascular risk factors in diabetic patients with hypertension.

Authors:  Nathaniel Winer; James R Sowers
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

Review 10.  Rehabilitative considerations for dental implants in the diabetic patient.

Authors:  Preeti Agarwal Katyayan; Manish Katyayan; Rupal J Shah
Journal:  J Indian Prosthodont Soc       Date:  2012-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.